Biotech / Finance

No surprise: Repatha reality is messier than initial reports suggested

From Health News Review
March 20, 2017 - 2:28pm
Ever since Amgen teased the public with claims of a landmark study showing that its new heart drug Repatha significantly reduced the risk of cardiovascular events, anticipation has been building for the day when Amgen would release the data to back up its bravado. That day finally came on Friday, and the wall-to-wall news coverage […]

Continue reading this article »